MERS virus cell entry mechanism is possible drug target
Date: Oct-15-2014 Researchers at Cornell University in Ithaca, NY, suggest blocking an
enzyme that helps the MERS virus enter host cells may lead to treatments for
the recently identified and deadly respiratory virus.
Middle East respiratory syndrome coronavirus (MERS-CoV), is a member of the
coronavirus family which in humans causes illnesses ranging from the common
cold to severe acute respiratory syndrome (SARS).
According to the World Health Organization (WHO), MERS was first identified
in Saudi Arabia in 2012, and both the virus and the disease it causes are
continuing to evolve.
Similar to other viruses known as enveloped viruses, coronaviruses enter
host cells by fusing with their cell membranes. Once inside, they use the host
cells' resources to make copies of themselves, escape and infect further
cells.
Furin protease activates the fusion of MERS with host cell membranes
Membrane fusion in coronaviruses is facilitated by a spike protein that is
activated by a protease enzyme at a location known as a cleavage site.
Prof. Whittaker and Dr. Millet suspect the MERS-CoV strain that infects humans mutated about 2.5 years ago from a strain in camels.
Writing in the Proceedings of the National Academy of Sciences, the
Cornell researchers describe how they discovered a protease called furin
activates the fusion process in the MERS virus at two cleavage sites. The study
is thought to be the first to describe a natural coronavirus with a spike
protein containing two furin cleavage sites.
Study authors Gary Whittaker, professor of virology, and Jean Millet, a
postdoctoral associate in his lab, suggest the extra cleavage site in the MERS
virus spike might be what allows the virus to spread more in the human or
animal.
Prof. Whittaker says with MERS, "the primary infection is in the lungs, and
even there it infects additional cell types." These additional cell types
include immune cells, which may offer the virus a way to spread to the rest of
the body, he adds.
The researchers also found furin activates the cleavage sites at different
stages of the virus life cycle. One point is when the virus is assembled inside
a host cell, another is when the virus makes it way out of the cell to the
surface, and a third is when the virus finds a new cell and fuses with its
membrane.
Treatment option may lie in blocking MERS furin at cell entry stage
They suggest one avenue for treatment could be to block furin at a specific
point in the host cell entry process.
Viruses mutate all the time, posing challenges for treatment developers. One
way they mutate is to change the protease they use for activation. This study
highlights an example of how flexible coronaviruses are in the way they alter
their cleavage mechanism: "They are extremely adaptable," says Dr. Millet.
Prof. Whittaker and Dr. Millet suspect the MERS-CoV strain that infects
humans mutated about 2.5 years ago from a strain in camels. This was
first suggested in 2013, when a Lancet study gave the first hint that
camels could be a reservoir for MERS.
Camels are an important feature of everyday life in many cultures in North
Africa and the Middle East, providing many opportunities for people to become
exposed to camel secretions such as milk and urine, which can be possible
routes to human infection, Prof. Whittaker explains.
At present human-to-human spread is relatively rare in MERS, except during
hospital-acquired-outbreaks, note the researchers.
The MERS outbreak in Saudi Arabia began in April and was largely confined to
hospitals. Cases have fallen, and it appears that the outbreak has been
contained.
Following a recent meeting of its International Health Regulations (IHR)
Emergency Committee to discuss the outbreak, a WHO statement notes that "although
transmission in health care settings is still occurring in small clusters,
transmission seems generally contained," and that current data suggests
transmission could be seasonal, "with an upsurge expected next spring."
In earlier statements the WHO have emphasized the importance of infection
prevention and control measures in containing the spread of MERS, and note it
is not possible to identify infected patients early because the early symptoms
are non-specific.
Poor infection prevention and control, lack of professional expertise and
equipment have been cited as reasons for the rapid spread of Ebola in the
epidemic currently raging in West Africa and threatening to spread to other
continents.
Written by Catharine Paddock PhD
Not to be reproduced without permission.
Follow @twitter
window.twttr = (function (d, s, id) {
var t, js, fjs = d.getElementsByTagName(s)[0];
if (d.getElementById(id)) return;
js = d.createElement(s); js.id = id;
js.src= "https://platform.twitter.com/widgets.js";
fjs.parentNode.insertBefore(js, fjs);
return window.twttr || (t = { _e: [], ready: function (f) { t._e.push(f) }
}(document, "script", "twitter-wjs"));
Courtesy: Medical News Today
Note: Any medical information available in this news section is not intended as a substitute for informed medical
advice and you should not take any action before consulting with a health care professional.